Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 17, 2026
Emulating Comparative Oncology Trials With Real-World Evidence Studies (ENCORE): Process Development and Methodological Considerations for Oncology Real-World Data.
Journal: Clinical pharmacology and therapeutics
Published: October 22, 2025
An FDA analysis of the association of tumor growth rate, overall survival, and progression-free survival in patients with metastatic non-small cell lung cancer.
Journal: The oncologist
Published: October 10, 2025
FDA Approval Summary: Tarlatamab for the Treatment of Extensive-Stage Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 28, 2025
FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 11, 2025
Most Common Symptomatic Adverse Reactions of Cancer Treatments From US Drug Labels (2015-2021) to Inform Selection of Patient-Reported Outcomes.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: February 12, 2024
Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials.
Journal: The oncologist
Published: August 10, 2023
Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis.
Journal: The Lancet. Oncology
Published: August 07, 2023
Continuation of Third-Generation Tyrosine Kinase Inhibitors in Second-Line Trials for EGFR-Mutated Non-Small-Cell Lung Cancer: Regulatory Considerations.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 08, 2023
US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 04, 2023
FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 17, 2023
FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 01, 2022
Last Updated: 09/26/2026